Navigation Links
Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Date:10/15/2010

PITTSBURGH, Oct. 15 /PRNewswire/ -- Precision Therapeutics announced today that its President and Chief Executive Officer Sean McDonald was recognized as CEO of the Year by the Pittsburgh Technology Council.

(Photo: http://photos.prnewswire.com/prnh/20101015/NE83126 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 )

The Tech 50 award recognizes the accomplishments of 50 of southwestern Pennsylvania's most successful entrepreneurs whose innovation and creativity have been used to strategically enhance the ideals and growth of their organization as well as the community and greater region. McDonald was selected by an independent panel of technology experts and the category awards were presented on October 14, 2010, at the Hilton Downtown Pittsburgh.

Sean joined Precision in 2001 and has since dedicated his career to developing innovative technologies with the goal of helping physicians to select customized treatment to meet the individual needs of each cancer patient. He most recently led Precision to earn a first place ranking as an industry leader in the health care division in the Pittsburgh region.  Because of Sean's passion, leadership and vision, Precision Therapeutics remains at the forefront of personalized diagnostics and research for individualized cancer therapy, with nearly 32,000 patient specimens sent for ChemoFx® testing and 18 active clinical trials.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.  Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.

For more information, please visit www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Applied Precision Installs New DeltaVision
2. OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University
3. Pinpoint precision: Delivering a biochemical payload to 1 cell
4. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
5. Stretching single molecules allows precision studies of interacting electrons
6. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
7. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
8. New statistical technique improves precision of nanotechnology data
9. Precision Stability Storage Announces Upcoming Expansion
10. NISTs LIDAR may offer peerless precision in remote measurements
11. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Personal Genome Diagnostics Inc. (PGDx) today announced that ... for Cancer Research (AACR) Annual Meeting 2017, being held April ... company also announced that five scientists associated with PGDx—two co-founders ... Annual AACR Team Science Award. ... Doug Ward , CEO of ...
(Date:3/29/2017)... Inc. (NASDAQ: VRML), a bio-analytical solutions company focused ... the fourth quarter and full year ended December ... year for us with our first clinical utility ... reimbursement progress with Medicare, positive medical policy coverage ... cleared our 2 nd generation product Overa ...
(Date:3/29/2017)... 2017 WuXi Biologics, a leading open-access ... biologics and a WuXi AppTec Affiliate, today announced ... Bioprocessing Excellence Award from IMAPAC, a leading consulting ... to recognize outstanding leaders and trend-setters of today, ... and biomanufacturing experts in the industry, along with ...
(Date:3/29/2017)... 29, 2017  Applied BioMath ( www.appliedbiomath.com ... to drug research and development, today announced ... Inc. for quantitative systems pharmacology (QSP) support ... the treatment of cancer. ... GLP toxicology studies and first-in-human dose predictions ...
Breaking Biology Technology:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
Breaking Biology News(10 mins):